Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kristoffer W. Balling"'
Autor:
Kristoffer W. Balling, Brian Lauritzen, Janne Olling, Mads Bjelke, Cecilia Augustsson, Ida Hilden, Anne Charlotte Hegelund, Kristin L. Abel
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 17(3)
Essentials Hemophilia patients on concizumab prophylaxis may need rFVIIa to treat breakthrough bleeds. Effect and safety of concizumab + rFVIIa were tested in vitro and in vivo. Concizumab + rFVIIa had no additive effects on bleeding in hemophilic ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528632585c3f57299874fefbf22845cf
https://pubmed.ncbi.nlm.nih.gov/30614620
https://pubmed.ncbi.nlm.nih.gov/30614620
Autor:
Berit Olsen Krogh, Brit B. Sørensen, L. Anders Svensson, Mirella Ezban, Kristoffer W. Balling, Jens Breinholt, Helle Heibroch Petersen, Jes Thorn Clausen, Lene Hansen, Christina Jespersgaard, Birgitte Friederichsen, Albrecht Gruhler, Andrew Neil Bowler, Brian Lauritzen, Lars Christian Petersen, Søren E. Bjørn, Thomas Egebjerg, Mette B. Hermit, Ida Hilden
Publikováno v:
Blood. 119:5871-5878
Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis. Improved treatment may be provided by drugs designed for subcutaneous and less frequent administrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b3cf7ab4b2f5e1d4080a2981c247ec
https://doi.org/10.1182/blood-2012-01-401620
https://doi.org/10.1182/blood-2012-01-401620
Autor:
Mirella Ezban, S. Segel, Thomas Dock Steenstrup, A. Bagger-Sørensen, Egon Persson, Stefan Lethagen, Niels Kristian Klausen, Ida Hilden, M. L. S. Christiansen, Dorthe Viuff, Brit B. Sørensen, Kristoffer W. Balling, Marianne Kjalke
Publikováno v:
Haemophilia. 16:878-887
The aim of this study was to evaluate the in vitro function of the new recombinant factor VIII (FVIII) compound, N8. The specific activity of N8 as measured in a FVIII:C one-stage clot assay was 9300±400 IU mg(-1) based on the analysis of seven indi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffe20fe7b346713b1960e4e536e062ab
https://doi.org/10.1111/j.1365-2516.2010.02333.x
https://doi.org/10.1111/j.1365-2516.2010.02333.x
Autor:
Christina Jespersgaard, Flemming Möller, Torben Elm, Wendy Kappers, Mikael Tranholm, Bernd Peschke, Henning R. Stennicke, Hermann Pelzer, Ditte M. Karpf, Anne K. Kristensen, Ida Hilden, Mirella Ezban, Are Bogsnes, Heidi L. Holmberg, Egon Persson, Anette A. Pedersen, Peter B. Johansen, Henrik Rahbek-Nielsen, Lars Thim, Eva H. N. Olsen, Kristine Øvlisen, Frederik Rode, C. N. Gudme, Søren E. Bjørn, Kristoffer W. Balling, Marianne Kjalke
Publikováno v:
Blood. 121(11)
Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a longer half-life was developed without changing the protein structure. FVIII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::253e09415aa1d23b0e2b5ef245ea33b0
https://pubmed.ncbi.nlm.nih.gov/23335368
https://pubmed.ncbi.nlm.nih.gov/23335368
Autor:
Mette Dahl Andersen, Lars Christian Petersen, Brit B. Sørensen, Henrik Agersø, Henrik Østergaard, Thomas N. Krogh, Lene Hansen, Karin Knobe, Pernille Holm, Anette A. Pedersen, Mette B. Hermit, Kristoffer W. Balling, Torben Elm, Mikael Tranholm, Timothy C. Nichols, Flemming Möller, Jais Rose Bjelke, Jørn Meidahl Petersen, Mirella Ezban, Søren E. Bjørn, Marie Louise S. Christiansen, Haleh Ahmadian
Publikováno v:
Blood. 118(8)
Current management of hemophilia B entails multiple weekly infusions of factor IX (FIX) to prevent bleeding episodes. In an attempt to make a longer acting recombinant FIX (rFIX), we have explored a new releasable protraction concept using the native
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbaabc81a11f6399a0797747f6229409
https://pubmed.ncbi.nlm.nih.gov/21700771
https://pubmed.ncbi.nlm.nih.gov/21700771
Publikováno v:
Thrombosis and Haemostasis. 104:860-861
The D2194G mutation is responsible for increased levels of FV1 in carriers of the factor V R2 haplotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a09da7eb550ac3005875e63bc041ae7
https://doi.org/10.1160/th10-03-0180
https://doi.org/10.1160/th10-03-0180